Premium
Survival rates and prognostic factors for infiltrating salivary duct carcinoma: Analysis of 228 cases from the Surveillance, Epidemiology, and End Results database
Author(s) -
Jayaprakash Vijayvel,
Merzianu Mihai,
Warren Graham W.,
Arshad Hassan,
Hicks Wesley L.,
Rigual Nestor R.,
Sullivan Maureen A.,
Seshadri Mukund,
Marshall James R.,
Cohan David M.,
Zhao Yujie,
Singh Anurag K.
Publication year - 2014
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.23350
Subject(s) - medicine , epidemiology , lymph node , oncology , surveillance, epidemiology, and end results , radiation therapy , adjuvant radiotherapy , stage (stratigraphy) , survival analysis , database , cancer registry , computer science , paleontology , biology
Background The survival rates and prognostic factors for salivary duct carcinoma (SDC) are not clear. Methods Survival estimates and prognostic factors were evaluated for 228 patients with SDC identified from the Surveillance, Epidemiology, and End Results (SEER) database. Results Median overall survival (OS) duration for patients with SDC was 79 months and 5‐year disease‐specific survival (DSS) rate was 64%. Among patients with SDC with lymph node involvement, larger primary tumor size (>3 cm) was associated with twice the risk of death ( p < .03). Factors predictive of improved DSS were age ( p = .01), tumor size ( p = .006), tumor grade ( p = .02), and lymph node involvement ( p < .001). Adjuvant radiotherapy did not improve survival when compared to surgery alone for early‐stage (I–II) disease ( p = .28). Conclusion Younger patients with SDC (<50 years) showed a better prognosis. Primary tumor size and lymph node involvement were independent and additive risk factors for poor prognosis. The role of adjuvant radiotherapy in the treatment of SDC needs to be explored further. © 2013 Wiley Periodicals, Inc. Head Neck 36 : 694–701, 2014